Susceptibility to SARS-CoV-2 Infection and Immune Responses to COVID-19 Vaccination Among Recipients of Solid Organ Transplants.

Authors:
Subramanian V.

Journal:
J Infect Dis

Publication Year: 2023

DOI:
10.1093/infdis/jiad152

PMCID:
PMC10401623

PMID:
37539762

View on PubMed View on PMC View Publisher
Journal Information

Full Title: J Infect Dis

Abbreviation: J Infect Dis

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Communicable Diseases

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Accumulation of Immunity in Heavy-Tailed Sexual Contact Networks Shapes Mpox Outbreak Sizes.
Murayama H; Pearson CAB; Abbott S and 5 more (2024) - Transparency Score: 4/6
A Phase 2 Extension Study Evaluating the Immunogenicity, Safety, and Tolerability of 3 or 4 Doses o…
Remich S; Kitchin N; Peterson J and 8 more (2024) - Transparency Score: 4/6
COVID-19 Recovery: Consistent Absence of Cerebrospinal Fluid Biomarker Abnormalities in Patients Wi…
Kanberg N; Grahn A; Stentoft E and 19 more (2024) - Transparency Score: 3/6
Diverging Maternal and Cord Antibody Functions From SARS-CoV-2 Infection and Vaccination in Pregnan…
Adhikari EH; Lu P; Kang YJ and 7 more (2024) - Transparency Score: 3/6
Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resista…
Chou S; Alain S; Cervera C and 9 more (2024) - Transparency Score: 4/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Potential conflicts of interest. The author certifies no potential conflicts of interest. The author has submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed."

Evidence found in paper:

"Notes: Acknowledgments. Medical writing and editorial assistance were provided by Jessica Nepomuceno, PhD, of MEDiSTRAVA in accordance with Good Publication Practice (GPP 2022) guidelines, funded by Moderna, Inc., and under the direction of the author.: Supplement sponsorship. This article appears as part of the supplement “COVID-19 Vaccination in the Immunocompromised Population,” sponsored by Moderna, Inc."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025